Publications:

POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy.

Clinical And Translational Medicine

Chen, Yan-Xing YX; Wang, Zi-Xian ZX; Yuan, Shu-Qiang SQ; Jiang, Teng-Jia TJ; Huang, You-Sheng YS; Xu, Rui-Hua RH; Wang, Feng F; Zhao, Qi Q

Publication Date: 2021-09

Variant appearance in text: POLE: R2026S

PubMed Link: 34586735

Variant Present in the following documents:

• CTM2-11-e524-s001.xlsx, sheet 2

View BVdb publication page

Distinctive genomic characteristics in POLE/POLD1-mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor.

Annals Of Translational Medicine

He, Junjun J; Ouyang, Wei W; Zhao, Wugan W; Shao, Lin L; Li, Bing B; Liu, Bihao B; Wang, Dejuan D; Han-Zhang, Han H; Zhang, Zhou Z; Shao, Liang L; Li, Wencai W

Publication Date: 2021-01

Variant appearance in text: POLE: R2026S

PubMed Link: 33569431

Variant Present in the following documents:

• Main text
• atm-09-02-129.pdf

View BVdb publication page